HC Wainwright & Co. Reiterates Buy on Celldex Therapeutics, Maintains $73 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Celldex Therapeutics (NASDAQ:CLDX) with a Buy and maintains $73 price target.
Union Pacific, Kosmos Energy, Fisker And Other Big Stocks Moving Higher On Monday
U.S. stocks traded higher, with the Dow Jones gaining more than 300 points on Monday. Here are some big stocks recording gains in today’s session.
Celldex Therapeutics Presented Data from Barzolvolimab Phase 1b Study in Chronic Spontaneous Urticaria at AAAAI 2023; Said Rapid, Profound And Durable Responses Across Multiple Dosing Groups With Favorable Safety Profile Observed
Celldex Therapeutics, Inc. (NASDAQ: CLDX) announced today updated data from the Company's Phase 1b clinical trial of barzolvolimab in patients with moderate to severe chronic spontaneous urticaria (CSU) refractory to antihistamines.
Guggenheim Maintains Buy on Celldex Therapeutics, Lowers Price Target to $63
Guggenheim analyst Yatin Suneja maintains Celldex Therapeutics (NASDAQ:CLDX) with a Buy and lowers the price target from $68 to $63.
Celldex Therapeutics Q3 Sales $407.00K Up From $153.00K YoY
Celldex Therapeutics (NASDAQ:CLDX) reported $407.00 thousand in sales this quarter. This is a 166.01 percent increase over sales of $153.00 thousand the same period last year.
HC Wainwright & Co. Maintains Buy Rating for Celldex Therapeutics: Here’s What You Need To Know
HC Wainwright & Co. has decided to maintain its Buy rating of Celldex Therapeutics (NASDAQ:CLDX) and raise its price target from $60.00 to $73.00.
Shares of Celldex Therapeutics are trading down 14.91% over the last 24 hours, at $22.94 per share.
Why U.S. Stocks Are Trading Higher, Manufacturing Report And More
U.S. stocks traded higher this morning, with the Dow Jones gaining more than 100 points on Friday.
HC Wainwright & Co. Maintains Buy on Celldex Therapeutics, Raises Price Target to $73
HC Wainwright & Co. analyst Joseph Hafling maintains Celldex Therapeutics (NASDAQ:CLDX) with a Buy and raises the price target from $60 to $73.
Recap of Tuesday’s Biotech Catalysts – End of the Day Summary
Ionis (NASDAQ: IONS) announced that Eplontersen met co-primary and secondary endpoints in interim analysis of the Phase 3 NEURO-TTRansform study for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN)
Ionis shares are trading low 4 percent at $35.10 in the after-hours session
